---
figid: PMC10149982__gr7
pmcid: PMC10149982
image_filename: gr7.jpg
figure_link: /pmc/articles/PMC10149982/figure/fig7/
number: Figure 7
figure_title: ''
caption: The potential targets of YZG-331. (A) YZG-331 increases GAD activity to promote
  GABA; (B) YZG-331 increases GABA, histamine and 1-methylhistamine levels in the
  rat brain; (C) YZG-331 may accelerate the inactivation of histamine via OCT3; The
  increased peripheral histamine permeates the pineal gland; (D) YZG-331 enhances
  intracellular histidine uptake and acts upon OCT3 to increase the outward transport
  of histamine in the periphery. Gln, glutamine; Glu, glutamate; GABA, γ-aminobutyric
  acid; His, histidine; HA, histamine; 1-methylHA, 1-methyl histamine; SA, succinic
  acid; TCA, tricarboxylic acid; GS, glutamine synthetase; PAG, phosphate-activated
  glutaminase; GAD, glutamic acid decarboxylase; HNMT, histamine N-methyltransferase;
  HDC, histidine decarboxylase; OCT3, organic cation transporter 3; PMAT, plasma membrane
  monoamine transporter; VMAT2, vesicular monoamine transporter 2; H1R, histamine
  H1 receptor; H2R, histamine H2 receptor; H3R, histamine H3 receptor. The histamine
  pathway in the brain has been illustrated according to a previous report.
article_title: Spatiotemporally resolved metabolomics and isotope tracing reveal CNS
  drug targets.
citation: Bo Jin, et al. Acta Pharm Sin B. 2023 Apr;13(4):1699-1710.
year: '2023'

doi: 10.1016/j.apsb.2022.11.011
journal_title: Acta Pharmaceutica Sinica. B
journal_nlm_ta: Acta Pharm Sin B
publisher_name: Elsevier

keywords:
- Ambient mass spectrometry imaging
- Spatiotemporally resolved metabolomics
- Isotope tracing
- Drug targets
- Central nervous system
- Drug candidate

---
